← Back
Data updated: Jul 17, 2026
PROVEPHARM SAS
Specialty Pharmaceuticals
PROVEPHARM SAS is a specialty pharmaceutical company with 4 FDA-approved products.
1946
Since
4
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
4 Small Molecules
PROVEPHARM SAS's Key Drugs
PROVEPHARM SAS's core commercial portfolio centers on BLUDIGO, PROVAYBLUE, ZYOGREEN — its most strategically important drugs approved in the last 15 years.
PROVEPHARM SAS's Recent FDA Approvals
PROVEPHARM SAS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
PROVEPHARM SAS's Therapeutic Areas
Disease areas where PROVEPHARM SAS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
PROVEPHARM SAS Pipeline Snapshot
Active clinical trials for PROVEPHARM SAS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BLUDIGO leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (0)
Company Info
- First Approval
- 1946-05-06
- Latest
- 2026-07-10
- Applications
- 4